<DOC>
	<DOCNO>NCT01382472</DOCNO>
	<brief_summary>In mechanistic pilot study 40 patient investigator compare finding patient treat early high dose statin therapy historic control KOMPIS study publish EHJ 200925 . The investigator want assess early high dose statin therapy patient treat primary PCI : 1. reduces area myocardial infarction , reduce volume improves remodelling assess MRI 2 day 2 month 2. improves microcirculation ( Decreased number patient MO ) assess first pas time estimate MRI 2 day 3. impact coronary blood flow assess intravascular registration TIMI frame count immediately PCI 4. reduce level CK-MB TnT measure area curve hospital stay improve neurohumoral profile assess Heart Rate Variability ( HRV ) neurohormone discharge 2 month follow-up 5. improves endothelial function assess flow mediate vasodilatation discharge 6. alters Peak VO2 1 6 month 7. reduce level CRP pro-inflammatory cytokine index hospitalization follow-up alters collagen turnover</brief_summary>
	<brief_title>Microcirculation In Acute Coronary Syndromes</brief_title>
	<detailed_description>Impairment myocardial microcirculation set AMI multifactorial etiology . This may due vasoactive factor include endothelin-1 , potent vasoconstricting peptide increasingly express active plaque . Oxidative stress ischaemia per se may also reduce bioavailability nitric oxide , contribute dysfunction myocardial microcirculation . Statins show benefit ACS patient believe decrease reperfusion injury ischemic event , promote plaque stabilization , reduce inflammation ACS patient . In patient admit acute coronary syndrome ( ACS ) , treatment statin &lt; 24 hour presentation associate low incidence death , stroke , reinfarction , heart failure , pulmonary edema compare delayed administration . 40 statin naive patient admit STEMI receive high dose statin Rosuvastatin 40 mg pre/per primary PCI continue treatment hospital stay . The high dose rosuvastatin choose achieve high plasma concentration early possible per condition myocardium risk . At discharge switch standard dose statin . Myocardial infarction assess Contrast enhance cardiac magnetic resonance 2 day 2 month . Microvascular obstruction ( MO ) may assess first- pas perfusion ( FPP ) delay hyper enhancement ( DHE ) MO define regional hypoperfusion first-pass perfusion previously describe . The investigator recently demonstrate MO verify CMR follow MI may allow early identification patient high risk LV remodel likely benefit pharmacological therapy . Blood test assessment collagen turnover , neurohumoral activation inflammation draw daily hospital stay . The Results compare finding statin naive patient tha KOMPIS trial treat high dose pre per operative statin</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Age &gt; 18 year Evidence acute ST elevation myocardial infarct . Planned primary PCI procedure . Obtained write informed consent . `` One vessel disease '' History previous myocardial infarction History valvular disease Ongoing therapy hyperlipidemia History heart failure Any active noncardiac comorbidity condition likely compromise patient cooperation survival followup period study . Pregnancy ( In doubt urine test employ treatment ) Lactating female Asians Previous muscle disease Reduced glomerular filtration Active hepatic disease Ongoing oral anticoagulation therapy Ongoing cyclosporine therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>STEMI</keyword>
	<keyword>PPCI</keyword>
	<keyword>Statins</keyword>
	<keyword>Infarct size</keyword>
</DOC>